

# Global EZH2 Targeted Therapy Market Opportunity, Approved Drug Price, Sales & Clinical Trials Insight 2026

<https://marketpublishers.com/r/G2C224D33937EN.html>

Date: January 2026

Pages: 120

Price: US\$ 2,500.00 (Single User License)

ID: G2C224D33937EN

## Abstracts

### Findings & Highlights:

Global & Regional Market Trends Insight

Number Of Approved EZH2 Targeted Therapies: 2 Therapies

Conditional Approval To EZH2 Therapy: 1 Therapy

Approved Therapy Dosage, Price & Sales Insight

Global EZH2 Targeted Therapy Clinical Trials Insight By Company, Country, Indication & Phase

Key Therapies Initiation & Completion Year Insight

Competitive Landscape

### Need For EZH2 Targeting Therapies & Why This Report

Inhibition of EZH2 (Enhancer of Zeste Homolog 2) has been at the forefront of contemporary therapy, especially for hematologic cancers and solid tumors. Inhibition of EZH2, an important catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), has recently become one of the primary areas being targeted in modern cancer treatment. Inhibiting EZH2 has significant implications in epigenetic modification,

specifically in histone H3 at residue 27, known as H3K27me3, which represses gene expression involved in cell differentiation, proliferation, or suppressing tumors. Aberrant EZH2 activity, either via overexpression, mutation, or PRC2 signaling, has been extensively linked in the etiology of many different forms of leukemia, including solid cancers. Consequently, EZH2 has become an attractive, biologically proven target for developing potential medicines for these malignancies. The present report comes at a critical time and is greatly needed, as it presents a comprehensive and critical overview of current developments in EZH2 targeting strategies, ranging from small molecule inhibitors to next generation epigenetic and combination based approaches.

The report provides an overview of the present clinical landscape, technology developments, important players, and strategic collaborations that are making EZH2 inhibition in oncology the next big thing. It underscores the increasing significance of EZH2 targeted therapies, providing insights into how the treatments may revolutionize the treatment of cancers, especially those with dysregulation or mutations in EZH2. With innovation speeding up, this report is an essential guide to following developments that will likely influence cancer care over the next few years.

### **EZH2 Targeting Therapies Clinical Trials Insight Covered In Report**

The report explores the most recent clinical trials of EZH2 Targeted therapies, providing in-depth insights into ongoing trials across various phases. It discusses not just the status of these trials as it stands now but also the encouraging outcomes coming from ongoing trials. Clinical activity is seen across a broad spectrum of cancer indications, such as follicular lymphoma, epithelioid sarcoma, peripheral T-cell lymphoma, and metastatic prostate cancer.

The report reviews the efficacy and safety profiles of different EZH2 inhibitors such as Tazverik (tazemetostat), Zemetostat, and Mevrometostat, giving an overview of patient response rates, progression free survival, and overall survival outcomes wherever possible. Moreover, the report identifies combination treatments, including those combining EZH2 inhibitors with immune checkpoint drugs or traditional chemotherapy drugs, with synergistic activities and increased therapeutic benefits. Based on clinical trial outcomes, the report identifies increasing optimism around EZH2 inhibition as a treatment approach as well as areas with the greatest potential for future innovations.

### **Leading Companies Active In R&D On EZH2 Targeting Therapies**

Several key companies are driving the development of EZH2 targeting treatments

forward. The report profiles and identifies the dominant players actively advancing EZH2 targeted drug development. Epizyme (Now Ipsen), the maker of Tazverik, is a trailblazer in the field and is continuing to grow its clinical trials in a variety of cancers. Other companies such as Hengrui Pharmaceuticals' Zemetostat and Pfizer's mevmrometostat are also making good progress in developing EZH2 inhibitors for both hematologic and solid cancers.

The report also discusses the research of upcoming biotech companies such as Treeline Biosciences, which is exploring novel mechanisms of action for EZH2 inhibition, and Hanmi Pharmaceutical, which is developing the dual EZH1/2 inhibitor HM97662. These firms are pursuing varied approaches, such as targeting the non-enzymatic activities of EZH2 and developing selective degraders, to breach resistance and increase therapeutic effectiveness against EZH2 inhibition. The report offers comprehensive company profiles, lead programs, and clinical approaches, giving stakeholders important insights.

### **Report Indicating Future Development Of EZH2 Targeting Therapies**

In the future, the prospects for EZH2 targeted therapies are very bright. The report details the anticipated course of the field, with sustained clinical investigation of EZH2 inhibitors in various cancers. The therapies will become progressively more personalized as more biomarkers are validated and incorporated into clinical decision making, enhancing the benefit risk profiles for patients. The future of EZH2 targeting is anticipated to involve a combination of inhibitors, degraders, and other new strategies designed to overcome resistance.

Besides, with the onset of next generation drugs such as dual EZH1/EZH2 inhibitors and selective EZH2 degraders, the area is set to provide more accurate and effective therapies. The report also predicts the growing significance of strategic collaborations and partnerships, which will keep on fueling innovation and taking new treatments to the market at a faster rate. As the technology advances and more new agents move into the pipeline, EZH2 inhibitors will become an important component of the oncology portfolio, bringing new hope to patients suffering with challenging and difficult to treat cancers.

## Contents

### **1. INTRODUCTION TO EZH2 TARGETED THERAPIES**

- 1.1 Overview Of EZH2 Targeted Therapies
- 1.2 Development & Evolution

### **2. MECHANISTIC INSIGHTS & THERAPEUTIC TARGETING OF EZH2**

- 2.1 Small Molecule Inhibitors
  - 2.1.1 Catalytic Inhibitors
  - 2.1.2 Allosteric inhibitors
- 2.2 EZH2 Degraders
- 2.3 Gene Silencing

### **3. GLOBAL EZH2 TARGETED THERAPY CLINICAL TRIALS OVERVIEW**

- 3.1 By Phase
- 3.2 By Country
- 3.3 By Company
- 3.4 By Indication

### **4. TAZVERIK ? FIRST APPROVED EZH2 TARGETED THERAPY**

- 4.1 Overview, Availability & Patent Insight
- 4.2 Dosage & Price Analysis
- 4.3 Sales Analysis

### **5. EZHARMI ? SECOND APPROVED EZH2 TARGETED THERAPY**

### **6. ZEPRUMETOSTAT (CONDITIONAL APPROVAL SEPTEMBER 2025)**

### **7. GLOBAL EZH2 TARGETED THERAPY MARKET ANALYSIS**

- 7.1 Current Market Scenario
- 7.2 Future Market Opportunities

### **8. GLOBAL EZH2 TARGETED THERAPY MARKET OPPORTUNITY BY REGION**

- 8.1 US
- 8.2 Europe
- 8.3 Japan
- 8.4 China
- 8.5 South Korea

## **9. EZH2 ROLE & TARGETED THERAPY DEVELOPMENT TRENDS BY INDICATION**

- 9.1 Cancer
  - 9.1.1 Solid Cancer
  - 9.1.2 Hematologic Malignancies
- 9.2 Autoimmune & Inflammatory Diseases
- 9.3 Neurological Disorders
- 9.4 Others

## **10. GLOBAL EZH2 TARGETED THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE**

- 10.1 Preclinical
- 10.2 Phase I
- 10.3 Phase I/II
- 10.4 Phase III
- 10.5 Registered

## **11. MARKETED EZH2 TARGETING THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE**

## **12. GLOBAL EZH2 TARGETED THERAPY MARKET DYNAMICS**

- 12.1 Market Drivers & Opportunities
- 12.2 Challenges & Strategic Solutions

## **13. COMPETITIVE LANDSCAPE**

- 13.1 Axter Therapeutics
- 13.2 Daiichi Sankyo
- 13.3 Evopoint Biosciences
- 13.4 GSK
- 13.5 Haihe Biopharma

13.6 Hanmi Pharmaceutical

13.7 Ipsen

13.8 Jiangsu HengRui Medicine.

13.9 Novartis

13.10 Pfizer

## List Of Tables

### LIST OF TABLES

Table 2-1: EZH2 Degradors - Classification

Table 2-2: EZH2 Gene Silencing - Challenges & Solutions In Clinical Translation

Table 5 -: Ezharmia ? Key Points

Table 6-1: Zeprumetostat ? Key Points

Table 9-1: EZH2 ? Involvement In Neurological Diseases

## List Of Figures

### LIST OF FIGURES

Figure 1-1: EZH2 ? Functions & Relevance As Therapeutic Target

Figure 1-2: Dual Biological Role Of EZH2

Figure 1-3: EZH2 Inhibitors - Regulatory Milestones

Figure 1-4: EZH2 Inhibition - Resistance Mechanisms

Figure 1-5: Timeline Of EZH2 research & Drug Milestones

Figure 2-1: EZH2 Inhibition - Mechanistic Overview

Figure 2-2: Catalytic vs. Allosteric EZH2 Inhibition

Figure 2-3: EZH2 Degraders - Mechanism Of Action

Figure 2-4: EZH2 Degradation - Downstream Biological Consequences In Cancer

Figure 2-5: EZH2 Degradation - Therapeutic Rationale

Figure 2-6: Overview Of Gene Silencing Approaches Targeting EZH2

Figure 2-7: EZH2 Gene Silencing - Advantages In Cancer Therapy

Figure 3-1: Global ? Number Of EZH2 Targeted Therapies In Clinical Trials By Phase, 2026

Figure 3-2: Global ? Number Of EZH2 Targeting Therapies In Clinical Trials By Country, 2026

Figure 3-3: Global ? Number Of EZH2 Targeting Therapies In Clinical Trials By Company, 2026

Figure 3-4: Global ? Number Of EZH2 Targeting Therapies In Clinical Trials By Indication, 2026

Figure 4-1: Tazverik ? Approval Year By Region

Figure 4-2: Tazverik ? Patent Filing & Expiration Year

Figure 4-3: Tazverik - Price Per Unit & Supply (US\$), January?2026

Figure 4-4: Tazverik ? Recommended Initial & Reduced Dose (mg/ Twice Daily)

Figure 4-5: Tazverik - Cost Monthly & Annual Treatment (US\$), January?2026

Figure 4-6: Global ? Tazverik Annual Sales (US\$ Million), 2022-2025

Figure 4-7: Global ? Tazverik Quarterly Sales (US\$ Million), Q1-Q3?2025

Figure 4-8: Global ? Tazverik Quarterly Sales (US\$ Million), Q1-Q4?2024

Figure 7-1: EZH2 Targeted Therapy Market - Future Opportunities

Figure 9-1: EZH2 - Cancer Hallmarks

Figure 9-2: EZH2 - Canonical vs Non-Canonical Functions

Figure 9-3: EPZ-IST-001 Phase 2 (NCT05023655) Study ? Initiation & Completion Year

Figure 9-4: 22 041 Phase 1 (NCT04846478) Study ? Initiation & Completion Year

Figure 9-5: EZH-1201 Phase 1 (NCT04241835) Study ? Initiation & Completion Year

Figure 9-6: CHN-PLAGH-BT-055 Phase 1/2 (NCT04407741) Study ? Initiation & Completion Year

Figure 9-7: SPLP-002-21F Phase 1/2 (NCT05467748) Study ? Initiation & Completion Year

Figure 9-8: EZH2 - Overview In Hematologic Malignancies

Figure 9-9: Hematologic Malignancies - Approved EZH2 Targeting Drugs

Figure 9-10: 22-07025095 Phase 1 (NCT05934838) Study ? Initiation & Completion Year

Figure 9-11: 23-06026184 Phase 2 (NCT05994235) Study ? Initiation & Completion Year

Figure 9-12: CLIN-60200-452 Phase 2 (NCT06068881) Study ? Initiation & Completion Year

Figure 9-13: NCI-2022-05327 Phase 1 (NCT05627245) Study ? Initiation & Completion Year

Figure 9-14: PTCL-IIT-SHR2554-SHR0302 Phase 2 (NCT06519526) Study ? Initiation & Completion Year

Figure 9-15: EZH2 - Roles Across Immune Cells

Figure 9-16: EZH2 In Autoimmune & Inflammatory Diseases

Figure 12-1: EZH2 Targeted Therapy Market - Drivers & Opportunities

Figure 12-2: EZH2 Targeted Therapy Market - Challenges & Strategic Solutions

## I would like to order

Product name: Global EZH2 Targeted Therapy Market Opportunity, Approved Drug Price, Sales & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/G2C224D33937EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2C224D33937EN.html>